Bright Minds Biosciences (DRUG) Research & Development (2019 - 2026)

Bright Minds Biosciences (DRUG) has 7 years of Research & Development data on file, last reported at $9.5 million in Q1 2026.

• Quarterly Research & Development rose 432.65% year-over-year to $9.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.0 million (up 683.14% YoY) and the FY2025 annual result came in at $8.1 million, up 831.13% from the prior year.
• Research & Development improved to $9.5 million in Q1 2026, from $4.1 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $9.5 million in Q1 2026 to a low of -$414373.2 in Q2 2024.
• A 5-year average of $1.9 million and a median of $1.1 million in 2022 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2024 — Research & Development tumbled 152.98% — and 2025, when it surged 2188.44%.
• Tracing DRUG's Research & Development over 5 years: stood at $1.1 million in 2022, then declined by 16.29% to $900190.9 in 2023, then dropped by 16.87% to $748325.8 in 2024, then soared by 442.43% to $4.1 million in 2025, then jumped by 134.39% to $9.5 million in 2026.
• The last three Research & Development figures came in at $9.5 million (Q1 2026), $4.1 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.